abstract |
The present invention belongs to the field of biomedicine, and relates to a pharmaceutical use of β2-microglobulin or an inhibitor thereof. In particular, the present invention relates to a use of β2-microglobulin or an inhibitor thereof in preparing a medicine for the treatment and/or prevention of Down's syndrome or Alzheimer's disease. β2-microglobulin can be used as an effective drug target for the prevention and treatment of Down's syndrome or Alzheimer's disease. |